Da Hee Han, PharmD

Most Recent Articles by Da Hee Han, PharmD

Imvexxy Approved for Moderate to Severe Dyspareunia Due to Menopause

Imvexxy Approved for Moderate to Severe Dyspareunia Due to Menopause

By

The FDA approval was supported by findings from a Phase 3, randomized, double-blind, placebo-controlled study that evaluated Imvexxy (4mcg and 10mcg) vs placebo from baseline to week 12.

Oral Contraceptive Taytulla Recalled Due to Packaging Error

Oral Contraceptive Taytulla Recalled Due to Packaging Error

By

A physician report indicates that 4 placebo (non-hormonal) capsules were placed in the first 4 days of therapy instead of active capsules.

First-of-Its-Kind Migraine Drug Receives FDA Approval

First-of-Its-Kind Migraine Drug Receives FDA Approval

By

The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).

FDA: Possible Risk of Neural Tube Birth Defects With Certain HIV Meds

FDA: Possible Risk of Neural Tube Birth Defects With Certain HIV Meds

By

The Agency has received reports of serious neural tube birth defects involving the brain, spine, and spinal cord in babies born to women who received dolutegravir for HIV treatment.

CDC: Recommendations on the Use of Heplisav-B Published

CDC: Recommendations on the Use of Heplisav-B Published

By

Benefits of protection with 2 doses administered over 1 month make the vaccine an important option for prevention of HBV.

More Articles by Da Hee Han, PharmD

Sign Up for Free e-newsletters